<b>EXISTENT COMMUNIST OF MONDOLLPTONIC TOOPONOOG!</b>			
<b>Groups</b>	<b>Total</b> а		Up-regulated Down-regulated
Control vs G1	791	334	457
Control vs G <sub>2</sub>	227	95	132
Control vs G3	293	54	239
G1 vs G2	370	284	86
G1 vs G3	723	386	337
G <sub>2</sub> vs G <sub>3</sub>	301	92	209

**Table S1.** Summary of transcriptome responses.

<sup>a</sup>Total number of differentially expressed probes. Differential expression of probes were determined using a fold change cutoff  $\pm$  ≥ or  $\leq$  2

## **Supplemental Figure Legends**

**Fig. S1.** *Sma*I Macro Restriction Profiles, Sequence Types and antimicrobial resistance profiles of ovine and bovine *C.jejuni* abortion-associated isolates. Similarity analysis was performed using the Dice coefficient, and clustering was performed by the unweighted pair-group method with arithmetic averages UPGMA (optimization, 1% and position tolerance, 1.5%) (Sanad et al., 2011; Ribot et al., 2001). Numbers on bootstraps represent Cophenetic correlations. Black boxes indicate resistance to different antimicrobials tested as described previously (Sanad et al., 2011; Sanad et al., 2013). Antimicrobials; azithromycin (AZ) (Breakpoint for a resistant *Campylobacter* isolate:  $\geq 8 \mu g$  ml<sup>-1</sup>); ciprofloxacin (CI) ( $\geq 4 \mu g$  ml<sup>-1</sup>); erythromycin (ER) ( $\geq 32 \mu g$ ml<sup>-1</sup>); gentamicin (GE) (≥8 µg ml<sup>-1</sup>); tetracycline (TE) (≥16 µg ml<sup>-1</sup>); florfenicol (FF) (≥8 µg ml<sup>-</sup> <sup>1</sup>); nalidixic acid (NA) ( $\geq 64 \mu g$  ml<sup>-1</sup>); telithromycin (TL) ( $\geq 8 \mu g$  ml<sup>-1</sup>); and clindamycin (CL) ( $\geq 8$  $\mu$ g ml<sup>-1</sup>). Minimal inhibitory concentrations (MIC) were determined according to the Clinical and Laboratory Standards Institute (CLSI 2006). Multilocus sequence typing (MLST) was conducted as described previously (Sanad et al., 2011; Dingle et al., 2001).

**Fig. S2:** Invasion and intracellular survival of ovine and bovine *C. jejuni* isolates in INT407 cells. Invasion and survival assays were performed as described previously (Sanad et al., 2011; Konkel et al., 1992; Prasad et al., 1996). **A.** CFU ml<sup>−</sup><sup>1</sup> representing the number of the internalized bacteria which could be retrieved after treatment of cells with gentamicin. **B.** Intracellular survival of *C. jejuni* isolates in INT 407cells. CFU ml<sup>−</sup><sup>1</sup> representing the numbers of internalized bacteria retrieved after 24 h of incubation. The INT407 were infected with 1:100 MOI of *C. jejuni* strains. *C. jejuni* 81–176 and NCTC11168 were used as controls. The detection limit of the assay is represented by the dashed line. Each bar represents the mean  $\pm$  SE of three independent experiments performed in duplicate for each sample (*P*<0.01).

Fig. S1



Fig. S2:



## **References**

- Clinical and Laboratory Standards Institute (CLSI), 2006: Performance standards for antimicrobial disk susceptibility tests, approved standard, 9th ed. Clinical and Laboratory Standards document M2-A9. Clinical and Laboratory Standards Institute, Wayne, PA.
- Dingle, K. E., F. M. Colles, D. R. A. Wareing, , Ure R., A. J. Fox, F. E. Bolton, H. J. Bootsma, R. J. L. Willems, R. Urwin, and M. C. J. Maiden, 2001: Multilocus sequence typing system for *Campylobacter jejuni*. *J. Clin. Microbiol*. 39, 14–23.
- Konkel, M. E,. and W. Cieplak Jr, 1992: Altered synthetic response of *Campylobacter jejuni* to cocultivation with human epithelial cells is associated with enhanced internalization. *Infect. Immun*. 60, 4945-4949.
- Prasad, K. N., T. N. Dhole, and A. Ayyagari, 1996: Adherence, invasion and cytotoxin assay of *Campylobacter jejuni* in HeLa and HEp-2 cells. *J. Diarrhoeal Dis. Res*. 14, 255–259.
- Ribot, E. R., C. Fitzgerald, K. Kubota, B. Swaminathan, and D. Barrett, 2001: Rapid pulsedfield gel electrophoresis protocol for subtyping of *Campylobacter jejuni*. *J. Clin. Microbiol*. 39, 1889–1894.
- Sanad, Y. M., I. I. Kassem, M. Abley, W. Gebreyes, J. T. LeJeune, and G. Rajashekara, 2011: Genotypic and phenotypic properties of cattle-associated *Campylobacter* and their implications to public health in the USA. *PLoS ONE*. 6, e25778.
- Sanad, Y. M., G. Closs Jr, A. Kumar, J. T. LeJeune, G. and Rajashekara, 2013: Molecular Epidemiology and Public Health Relevance of *Campylobacter* Isolated from Dairy Cattle and European Starlings in Ohio, USA. *Foodborne Path. Dis*. 10, 229-236.